Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
CURE4d
Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...
Clinical Trials Arena on MSN3d
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement
The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.
Zacks Investment Research on MSN3d
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data ...
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...
Fierce Biotech4d
Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
MPR3d
Relacorilant Looks Promising for Platinum-Resistant Ovarian Cancer
The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.
Corcept Therapeutics announces ROSELLA trial meets primary endpoint
Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...
Corcept Therapeutics Shares Soar on Positive Ovarian Cancer Treatment Trial Results
Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...